Marc Bertrand
Papers
1
Total Citations
3
H-Index
1
About
Marc Bertrand is a medicinal chemist whose work bridges combinatorial chemistry and targeted drug discovery. His primary research focuses on the design and optimization of enzyme inhibitors, particularly through the innovative use of peptide libraries. His most notable contribution, detailed in a 2001 study, involved the robotic synthesis of a massive 331,776-member tetrapeptide library on solid phase. By employing a systematic deconvolution strategy, his team identified potent inhibitors of S-farnesyltransferase, a key enzyme in cancer biology. Crucially, Bertrand advanced these hits into nonpeptide ligands, demonstrating a powerful pathway from complex peptide libraries to more drug-like, stable compounds. While his highly specialized work has garnered 3 citations, its methodological impact is significant, showcasing a rigorous, high-throughput approach to lead optimization. Bertrand’s achievements lie in pioneering solid-phase synthesis and deconvolution techniques that continue to inform the rational design of nonpeptide therapeutics, making his research a foundational reference for scientists exploring targeted enzyme inhibition and combinatorial library strategies.
Research Focus
Key Achievements
Top Papers
- 1